USC researcher Kim Staats looks for the pattern in sporadic cases of ALS

Kim Staats (Photo by Cristy Lytal)
Kim Staats (Photo by Cristy Lytal)

USC postdoctoral researcher Kim Staats found her calling when a childhood neighbor was diagnosed with ALS, a paralyzing and fatal neurodegenerative disease. At the time, Staats was pursuing bachelor’s and master’s degrees in kinesiology at Free University Amsterdam (Vrije Universiteit Amsterdam), with plans to either practice or teach physical therapy after graduation.

As a kinesiology student, Staats asked herself: What if people with ALS do a lot more exercise? Would that give them a muscular buffer against this paralysis?

“I wrote a literature review on that, just for my courses, and realized very quickly that I couldn’t understand the system properly without understanding neurosciences better,” she said.

Determined to understand ALS—which eventually claimed the life of her neighbor, his mother and his brother—she undertook a second master’s degree in neurosciences at Free University Amsterdam.

After graduation, Staats, who is Canadian and Dutch, spent a year teaching English in Tokyo. She then pursued her PhD at the University of Leuven in Belgium, where she joined the laboratory of Ludo Van Den Bosch, under the co-mentorship of Wim Robberecht. She studied mice as a way to understand the molecular mechanisms that cause motor neuron death in ALS, and to explore possible treatments.

She pursued postdoctoral training for two years in the laboratory of Roel A. Ophoff at UCLA, where she studied the human genetics underlying ALS.

She then chose to continue her postdoctoral research in the laboratory of Justin Ichida at USC. She was drawn to the clinical relevance of the research in the Ichida Lab, which explores ALS mechanisms and screens therapeutic drug candidates using patient-derived motor nerve cells.

Shortly after arriving in the Ichida Lab, Staats was awarded a three-year, $180,000 development grant from the Muscular Dystrophy Association (MDA).

“I’m grateful for the MDA grant, which is truly enabling my ALS research at USC,” she said. “It is also a bit of a compliment, as it’s an honor to know that I can bring in grants sometimes, so at least there’s a reason I could believe I could be a principal investigator, a PI with my own lab someday.”

With this support, she is exploring the causes for what is known as “sporadic” ALS—which occurs in people with no relatives known to have the disease.

In collaboration with another postdoctoral researcher, Toru Sugawara, Staats has identified a candidate gene that might contribute to sporadic ALS. She is now working to clarify how a mutation in this gene might contribute to the death of motor nerve cells, the chief symptom of ALS. By studying the role of this gene, she aims to increase the understanding of not only what causes ALS, but also how to treat it.

“Ninety percent of all ALS patients, on average, are sporadic, and most of the work is being done on the familial cases because, of course, it’s easier. It’s genetic. We can fathom this,” said Staats. “So I really like the MDA project because it allows us to look at the sporadic component.”

In addition to challenging herself in the laboratory, Staats enjoys exploring Los Angeles—from the hiking trails in the mountains, to cafes in Downtown neighborhoods including the Arts District and Little Tokyo. She also appreciates the city’s colorful history, and lives in a converted hotel, built in 1927, in Koreatown.

“It has a penthouse on the roof in which Clark Gable lived and Ronald Reagan,” she said. “It’s old-fashioned Hollywood. We have a mail chute that still works. And we have the first rooftop pool in all of LA. It’s tiny. It’s not even heated. But it’s a historical part of LA, and I love that.”

As for the future, whether she remains in LA or explores new opportunities abroad, Staats will remain devoted to the study of ALS and the quest for better treatments.

“ALS is one of the most devastating diseases someone can encounter or suffer from. There’s no cure available. There are two drugs currently available, but they only prolong the life of an ALS patient by a number of months,” she said. “That’s not enough.”

Mentioned in this article: Justin Ichida, PhD